Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Simply Wall StDec 26 06:01 ET

Is Mersana Therapeutics (NASDAQ:MRSN) Weighed On By Its Debt Load?

Simply Wall StDec 17 07:08 ET

Alphina Therapeutics Strengthens Management Team With Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer

PR NewswireDec 17 07:00 ET

BTIG Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsDec 16 20:32 ET · Ratings

Promising Clinical Data and Valuation Support Mersana Therapeutics' Buy Recommendation

TipRanksDec 16 19:47 ET

Mersana Therapeutics Transferred With Buy Rating at Citi

TipRanksNov 15 05:40 ET · Ratings